Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study - Concepedia

Concepedia

Publication | Closed Access

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study

17

Citations

24

References

2023

Year

Li-Anne H Douma, Ferry Lalezari, Vincent van der Noort, Jeltje F. de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A. Burgers,

The Lancet Oncology

Single-arm Phase 2Third-line PatientsMedicinePathologyPleural EffusionPleural DiseaseOncologyRadiation OncologyPleural Mesothelioma

References

	Year	Citations

Page 1

Page 1